MaxCyte, Inc. (NASDAQ:MXCT) EVP Sells $54,529.93 in Stock

MaxCyte, Inc. (NASDAQ:MXCT) EVP Thomas M. Ross sold 13,531 shares of the company’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $4.03, for a total value of $54,529.93. Following the sale, the executive vice president now owns 25,000 shares of the company’s stock, valued at approximately $100,750. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

MaxCyte Price Performance

MXCT stock opened at $4.49 on Friday. The stock’s fifty day simple moving average is $4.43 and its two-hundred day simple moving average is $4.47. MaxCyte, Inc. has a 1-year low of $2.45 and a 1-year high of $5.55.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.05. MaxCyte had a negative return on equity of 15.68% and a negative net margin of 83.00%. The business had revenue of $11.34 million for the quarter, compared to analysts’ expectations of $7.75 million. On average, equities research analysts forecast that MaxCyte, Inc. will post -0.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cadian Capital Management LP purchased a new position in MaxCyte in the fourth quarter worth $26,531,000. Chevy Chase Trust Holdings LLC lifted its position in shares of MaxCyte by 2,182.6% during the 1st quarter. Chevy Chase Trust Holdings LLC now owns 1,296,397 shares of the company’s stock valued at $5,432,000 after buying an additional 1,239,602 shares during the last quarter. Mudita Advisors LLP lifted its position in shares of MaxCyte by 35.3% during the 4th quarter. Mudita Advisors LLP now owns 1,881,349 shares of the company’s stock valued at $8,842,000 after buying an additional 490,491 shares during the last quarter. Willis Investment Counsel purchased a new position in shares of MaxCyte during the 4th quarter valued at $2,585,000. Finally, Victory Capital Management Inc. lifted its position in shares of MaxCyte by 23.0% during the 4th quarter. Victory Capital Management Inc. now owns 12,316 shares of the company’s stock valued at $58,000 after buying an additional 2,306 shares during the last quarter. Hedge funds and other institutional investors own 68.81% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Stephens reiterated an “overweight” rating and set a $11.00 price target on shares of MaxCyte in a report on Tuesday, April 23rd.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.